Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. announced the appointment of Nicholas Maestas as its new Chief Financial Officer, effective immediately. Maestas brings over a decade of financial leadership experience from clinical-stage biotechnology companies, including his previous role as CFO at Tempest Therapeutics. He succeeds Svai Sanford, who departed in May 2026 to pursue other opportunities. The company highlighted Maestas's expertise in biopharma capital markets and corporate strategy.

Rani Therapeutics Holdings, Inc. entered into a securities purchase agreement with institutional investors to raise approximately $20.0 million in gross proceeds. The offering includes 12,476,637 shares of Class A common stock at $1.07 per share and pre-funded warrants for 6,214,953 shares at $1.0699 per warrant. The closing is expected around May 27, 2026, with placement agents receiving a 6.0% cash fee.

Rani Therapeutics announced a registered direct offering to raise approximately $20.0 million in gross proceeds. The offering includes the sale of 12,476,637 shares of Class A common stock at $1.07 per share and 6,214,953 pre-funded warrants at $1.0699 per warrant. A sovereign wealth fund is leading the investment, alongside other new and existing healthcare-focused funds, with the closing expected around May 27, 2026.

Rani Therapeutics reported a net loss of $8.0 million for Q1 2026, a significant improvement from $12.7 million in Q1 2025. Contract revenue surged to $1.7 million, up from $0.17 million in the prior year, largely due to the Chugai collaboration. The company maintains $43.4 million in cash, cash equivalents, and marketable securities, which is expected to be sufficient to fund operations for at least the next twelve months.

Rani Therapeutics Holdings, Inc. announced its first quarter 2026 financial results, reporting a reduced net loss of $8.0 million and increased contract revenue of $1.7 million. Concurrently, the company received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, initiating a 180-day period to regain compliance. Additionally, CFO Svai Sanford will resign following the appointment of a successor, though his departure is not due to disagreements. The company also provided corporate updates, including the advancement of its RT-114 Phase 1 study and new strategic appointments.

Rani Therapeutics announced that CFO Svai Sanford will transition from his role, with a search for a successor initiated. The company also reported Q1 2026 financial results, showing a reduced net loss of $8.0 million and increased contract revenue of $1.7 million. Additionally, Rani strengthened its leadership team with the promotion of Alireza Javadi to CTO and the appointments of Jesper Høiland as Head of Strategy and Dr. Sara Kenkare-Mitra as Strategic Advisor, while continuing to advance its Phase 1 study of RT-114 for obesity.